← Back to headlines
FDA Approves Priovant's Lisraya for Dermatomyositis Treatment
The U.S. Food and Drug Administration has granted approval to Lisraya, developed by Priovant, marking a new therapeutic option for patients suffering from dermatomyositis.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Bitcoin Drops Below $78,000 Following Fed Chair’s Hawkish Jackson Hole Remarks
32m ago
College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales
1h ago
Fed Chair Warsh Warns of Potential Rate Hikes Amid Stubborn Inflation
2h ago
Temasek Backs Singapore Airlines’ Strategic Investment in Air India
2h ago